SCHEMBL5135641

SCHEMBL5135641

Cc1cccc(CN(C(=O)c2cccc3c2-c2ccccc2C3)C2Cc3ccccc3C2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 2/20 0.39
HCRTR2 O43614 2/20 0.39
POLB P06746 2/20 0.39
HTR2B P41595 1/20 0.39
HSP90AA1 P07900 1/20 0.38
TACR1 P25103 2/20 0.38
TP53 P04637 1/20 0.38
KMT2A Q03164 2/20 0.37
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
RAB9A P51151 1/20 0.36
PARP1 P09874 1/20 0.36
PARP2 Q9UGN5 1/20 0.36
LPAR1 Q92633 1/20 0.35
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
CASP6 P55212 1/20 0.34
MC4R P32245 1/20 0.34
MC5R P33032 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136090 0.89 POLB (0.43) HCRTR1HCRTR2POLBHTR2BKMT2A
SCHEMBL5137467 0.85 KMT2A (0.48) HSP90AA1TACR1TP53KMT2ASLC6A2
SCHEMBL5358837 0.84 LPAR1 (0.43) HSP90AA1TACR1TP53KMT2ASLC6A2
SCHEMBL5135910 0.83 RAB9A (0.45) HSP90AA1TACR1TP53KMT2ASLC6A2
SCHEMBL5134846 0.83 POLB (0.40) HCRTR1HCRTR2POLBHTR2BHSP90AA1
SCHEMBL5136851 0.82 ALDH1A1 (0.42) HSP90AA1KMT2AMEN1GAAALDH1A1
SCHEMBL5373175 0.79 TP53 (0.49) HCRTR1HCRTR2POLBTP53KMT2A
SCHEMBL5135980 0.79 LMNA (0.44) HSP90AA1TACR1TP53KMT2ARAB9A
SCHEMBL5138056 0.79 MAPT (0.46) POLBHTR2BTP53RAB9AKDM4E
SCHEMBL5134589 0.78 TP53 (0.41) POLBHSP90AA1TACR1TP53KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed